Daratumumab plus Bortezomib/Lenalidomide/ Dexamethasone in Patients With Transplant-ineligible or Transplant-deferred Newly Diagnosed Multiple Myeloma: Results of the Phase 3 CEPHEUS Study

被引：0

作者：

Usmani, Saad Z. ^{[1
]}

Facon, Thierry ^{[2
]}

Hungria, Vania ^{[3
]}

Bahlis, Nizar J. ^{[4
]}

Venner, Christopher P. ^{[5
,6
]}

Braunstein, Marc ^{[7
]}

Pour, Ludek ^{[8
]}

Marti, Josep ^{[9
]}

Basu, Supratik ^{[10
,11
]}

Cohen, Yael C. ^{[12
]}

Matsumoto, Morio ^{[13
]}

Suzuki, Kenshi ^{[14
]}

Hulin, Cyrille ^{[15
]}

Grosicki, Sebastian ^{[16
]}

Legiec, Wojciech ^{[17
]}

Beksac, Meral ^{[18
]}

Maiolino, Angelo ^{[19
]}

Liu, Weiping ^{[20
]}

Wang, Jianping ^{[21
]}

Krevvata, Maria ^{[21
]}

Lopez-Masi, Lorena ^{[22
]}

Carey, Jodi ^{[21
]}

Rowe, Melissa ^{[23
]}

Carson, Robin ^{[21
]}

Zweegman, Sonja ^{[24
]}

机构：

[1] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA

[2] Univ Lille, CHU Lille, Serv Malad Sang, Lille, France

[3] Clin Med Sao Germano, Sao Paulo, Brazil

[4] Univ Calgary, Arnie Charbonneau Canc Inst, Calgary, AB, Canada

[5] Univ Alberta, Cross Canc Inst, Dept Med Oncol, Edmonton, AB, Canada

[6] Univ British Columbia, BC Canc Vancouver Ctr, Vancouver, BC, Canada

[7] NYU Langone Hlth, Perlmutter Canc Ctr, New York, NY USA

[8] Univ Hosp Brno, Brno, Czech Republic

[9] Hosp Univ Mutua Terrassa, Terrassa, Spain

[10] Royal Wolverhampton NHS Trust, Wolverhampton, England

[11] Univ Wolverhampton, CRN West Midlands, NIHR, Wolverhampton, England

[12] Tel Aviv Univ, Fac Med & Hlth Sci, Tel Aviv Sourasky Ichilov Med Ctr, Tel Aviv, Israel

[13] Natl Hosp Org, Dept Hematol, Shibukawa Med Ctr, Gunma, Japan

[14] Japanese Red Cross Med Ctr, Dept Hematol, Tokyo, Japan

[15] Univ Hosp, Dept Hematol, Hop Haut Leveque, Pessac, France

[16] Med Univ Silesian, Sch Publ Hlth, Dept Hematol & Canc Prevent, Katowice, Poland

[17] St John Dukla Oncol Ctr Lublin Land, Dept Hematol & Bone Marrow Transplantat, Lublin, Poland

[18] Istinye Univ, Ankara Liv Hosp, Ankara, Turkiye

[19] Inst Amer Ensino Pesquisa & Inovacao, Rio De Janeiro, Brazil

[20] Janssen Res & Dev, Shanghai, Peoples R China

[21] Janssen Res & Dev LLC, Spring House, PA USA

[22] Janssen Res & Dev LLC, Raritan, NJ USA

[23] Janssen Res & Dev LLC, High Wycombe, Bucks, England

[24] Vrije Univ Amsterdam, Dept Hematol, Canc Ctr Amsterdam, Amsterdam UMC, Amsterdam, Netherlands

来源：

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2024年 / 24卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

OA-63

引用

页码：S288 / S289

页数：2

共 50 条

[21] Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) Alone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of the Phase 3 Maia Study
Kumar, Shaji K.
Moreau, Philippe
Bahlis, Nizar Jacques
Facon, Thierry
Plesner, Torben
Orlowski, Robert Z.
Basu, Supratik
Nahi, Hareth
Hulin, Cyrille
Quach, Hang
Goldschmidt, Hartmut
O'Dwyer, Michael
Perrot, Aurore
Venner, Christopher P.
Weisel, Katja
Raje, Noopur
Tiab, Mourad
Macro, Margaret
Frenzel, Laurent
Leleu, Xavier
Pei, Huiling
Krevvata, Maria
Carson, Robin
Borgsten, Fredrik
Usmani, Saad
BLOOD, 2022, 140 : 10150 - 10153
[22] Isatuximab, Plus Bortezomib, Lenalidomide, and Dexamethasone (VRd) for Newly Diagnosed Multiple Myeloma (NDMM) Transplant-ineligible Patients: Frailty Subgroup Analysis of IMROZ
Manier, Salomon
Dimopoulos, Meletios-Athanasios
Leleu, Xavier
Moreau, Philippe
Cavo, Michele
Goldschmidt, Hartmut
Orlowski, Robert Z.
Tron, Muriel
Tekle, Christina
Bregeault, Marie-France
Shafer, Andrea
Beksac, Meral
Facon, Thierry
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S290 - S291
[23] Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Myeloma
Benboubker, Lotfi
Dimopoulos, Meletios A.
Dispenzieri, Angela
Catalano, John
Belch, Andrew R.
Cavo, Michele
Pinto, Antonello
Weisel, Katja
Ludwig, Heinz
Bahlis, Nizar
Banos, Anne
Tiab, Mourad
Delforge, Michel
Cavenagh, Jamie
Geraldes, Catarina
Lee, Je-Jung
Chen, Christine
Oriol, Albert
de la Rubia, Javier
Qiu, Lugui
White, Darrell J.
Binder, Daniel
Anderson, Kenneth
Fermand, Jean-Paul
Moreau, Philippe
Attal, Michel
Knight, Robert
Chen, Guang
Van Oostendorp, Jason
Jacques, Christian
Ervin-Haynes, Annette
Avet-Loiseau, Herve
Hulin, Cyrille
Facon, Thierry
NEW ENGLAND JOURNAL OF MEDICINE, 2014, 371 (10): : 906 - 917
[24] Daratumumab plus lenalidomide/bortezomib/dexamethasone in Black patients with transplant-eligible newly diagnosed multiple myeloma in GRIFFIN
Ajay K. Nooka
Jonathan L. Kaufman
Cesar Rodriguez
Andrzej Jakubowiak
Yvonne Efebera
Brandi Reeves
Tanya Wildes
Sarah A. Holstein
Larry D. Anderson
Ashraf Badros
Leyla Shune
Ajai Chari
Huiling Pei
Annelore Cortoos
Sharmila Patel
J. Blake Bartlett
Jessica Vermeulen
Thomas S. Lin
Paul G. Richardson
Peter Voorhees
Blood Cancer Journal, 12
[25] Phase 3 MAIA Study: Overall Survival (OS) Results with Daratumumab, Lenalidomide, and Dexamethasone (DRd) vs Lenalidomide and Dexamethasone (Rd) in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma (TIE-NDMM)
Orlowski, Robert
Facon, Thierry
Kumar, Shaji
Plesner, Torben
Moreau, Philippe
Bahlis, Nizar
Basu, Supratik
Nahi, Hareth
Hulin, Cyrille
Quach, Hang
Goldschmidt, Hartmut
O'Dwyer, Michael
Perrot, Aurore
Venner, Christopher
Weisel, Katja
Mace, Joseph
Raje, Noopur
Tiab, Mourad
Macro, Margaret
Frenzel, Laurent
Leleu, Xavier
Ahmadi, Tahamtan
Wang, Jianping
Van Rampelbergh, Rian
Uhlar, Clarissa
Tromp, Brenda
Delioukina, Maria
Vermeulen, Jessica
Usmani, Saad
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S424 - S425
[26] Daratumumab plus lenalidomide/bortezomib/dexamethasone in Black patients with transplant-eligible newly diagnosed multiple myeloma in GRIFFIN
Nooka, Ajay K.
Kaufman, Jonathan L.
Rodriguez, Cesar
Jakubowiak, Andrzej
Efebera, Yvonne
Reeves, Brandi
Wildes, Tanya
Holstein, Sarah A.
Anderson, Larry D., Jr.
Badros, Ashraf
Shune, Leyla
Chari, Ajai
Pei, Huiling
Cortoos, Annelore
Patel, Sharmila
Bartlett, J. Blake
Vermeulen, Jessica
Lin, Thomas S.
Richardson, Paul G.
Voorhees, Peter
BLOOD CANCER JOURNAL, 2022, 12 (04)
[27] Overall survival and progression-free survival by treatment duration with Daratumumab plus Lenalidomide/Dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: phase 3 MAIA study
Moreau, Philippe
Facon, Thierry
Kumar, Shaji
Plesner, Torben
Orlowski, Robert Z.
Bahlis, Nizar
Basu, Supratik
Nahi, Hareth
Hulin, Cyrille
Quach, Hang
Goldschmidt, Hartmut
O'Dwyer, Michael
Perrot, Aurore
Venner, Christopher
Weisel, Katja
Mace, Joseph R.
Raje, Noopur
Tiab, Mourad
Macro, Margaret
Frenzel, Laurent
Leleu, Xavier
Pei, Huiling
Tromp, Brenda
Delioukina, Maria
Usmani, Saad Z.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S1 - S1
[28] Isatuximab, lenalidomide, dexamethasone and bortezomib in transplant-ineligible multiple myeloma: the randomized phase 3 BENEFIT trial
Leleu, Xavier
Hulin, Cyrille
Lambert, Jerome
Bobin, Arthur
Perrot, Aurore
Karlin, Lionel
Roussel, Murielle
Montes, Lydia
Cherel, Brieuc
Chalopin, Thomas
Slama, Borhane
Chretien, Marie-Lorraine
Laribi, Kamel
Dingremont, Claire
Roul, Christophe
Mariette, Clara
Rigaudeau, Sophie
Calmettes, Claire
Dib, Mamoun
Tiab, Mourad
Vincent, Laure
Delaunay, Jacques
Santagostino, Alberto
Macro, Margaret
Bourgeois, Emmanuelle
Orsini-Piocelle, Frederique
Gay, Julie
Bareau, Benoit
Bigot, Noemie
Vergez, Francois
Lebreton, Pierre
Tabrizi, Reza
Waultier-Rascalou, Agathe
Frenzel, Laurent
Le Calloch, Ronan
Chalayer, Emilie
Braun, Thorsten
Lachenal, Florence
Corm, Selim
Kennel, Celine
Belkhir, Rakiba
Blade, Jean-Sebastien
Joly, Bertrand
Richez-Olivier, Valentine
Gardeney, Helene
Demarquette, Helene
Robu-Cretu, Daniela
Garderet, Laurent
Newinger-Porte, Muriel
Kasmi, Amine
NATURE MEDICINE, 2024, 30 (08) : 2235 - 2241
[29] Belantamab mafodotin, lenalidomide and dexamethasone in transplant-ineligible patients with newly diagnosed multiple myeloma: part 1 results of a phase I/II study
Terpos, Evangelos
Gavriatopoulou, Maria
Ntanasis-Stathopoulos, Ioannis
Malandrakis, Panagiotis
Fotiou, Despina
Migkou, Magdalini
Theodorakakou, Foteini
Spiliopoulou, Vasiliki
Kostopoulos, Ioannis V.
Syrigou, Rodanthi-Eleni
Eleutherakis-Papaiakovou, Evangelos
Gkolfinopoulos, Stavros
Tsitsilonis, Ourania E.
Kastritis, Efstathios
Dimopoulos, Meletios A.
HAEMATOLOGICA, 2024, 109 (08) : 2594 - 2605
[30] Cost-effectiveness of lenalidomide plus dexamethasone vs bortezomib plus melphalan and prednisone in transplant-ineligible US patients with newly-diagnosed multiple myeloma
Usmani, S. Z.
Cavenagh, J. D.
Belch, A. R.
Hulin, C.
Basu, S.
White, D.
Nooka, A.
Ervin-Haynes, A.
Yiu, W.
Nagarwala, Y.
Berger, A.
Pelligra, C. G.
Guo, S.
Binder, G.
Gibson, C. J.
Facon, T.
JOURNAL OF MEDICAL ECONOMICS, 2016, 19 (03) : 243 - 258

← 1 2 3 4 5 →